Skip to Content

Investor Relations

BioScrip®, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S...
Read More

Corporate Profile

BioScrip®, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Overview

News Releases

Date Title and Summary
Toggle Summary BioScrip to Host Third Quarter Results Call
DENVER , Oct. 16, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will release its third quarter 2017 financial results on Thursday,
Toggle Summary BioScrip Announces Availability of ALS Home Infusion Therapy
DENVER , Oct. 05, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, is pleased to announce that it can now dispense and administer Radicava® (edaravone), the first treatment
Toggle Summary BioScrip Reports Second Quarter 2017 Financial Results
– Net revenue of $218.1 million , including core product mix of 73.1% compared to 60.3% in the prior year – Net loss from continuing operations of $28.7 million , compared to $8.3 million in the prior year, reflecting increased non-cash expenses and interest – Adjusted EBITDA of $10.0 million ,